Oculis Holding AG (OCS) Assets Average (2023 - 2026)
Oculis Holding AG's (OCS) quarterly Assets Average came in at $303.4 million in Q1 2026, up 66.49% year-on-year from $182.2 million in Q1 2025, and up 20.15% quarter-over-quarter from $252.5 million in Q4 2025.
Oculis Holding AG (OCS) Assets Average (2023 - 2026) Analysis & Trends
Oculis Holding AG's Assets Average history runs 4 years deep, the most recent figure standing at $303.4 million for Q1 2026.
- On a quarterly basis, Assets Average rose 66.49% year-over-year to $303.4 million in Q1 2026; TTM through Mar 2026 was $303.4 million, a 66.49% increase from a year earlier, with the FY2025 full-year figure at $210.7 million, up 59.54% from the prior year.
- Assets Average advanced to $303.4 million in Q1 2026 per OCS's latest filing, from $252.5 million in the prior quarter.
- Across five years, Assets Average topped out at $303.4 million in Q1 2026 and bottomed at $121.0 million in Q1 2024.
- The 4-year median for Assets Average is $149.2 million (2024), against an average of $182.4 million.
- Across the five-year window, Assets Average increased 0.82% in 2024 and jumped 78.86% in 2025, its largest moves.
- Year by year, Assets Average stood at $137.4 million in 2023, then advanced by 2.72% to $141.2 million in 2024, then soared by 78.86% to $252.5 million in 2025, then climbed by 20.15% to $303.4 million in 2026.
- Per Business Quant, the three latest OCS Assets Average figures stand at $303.4 million (Q1 2026), $252.5 million (Q4 2025), and $214.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.30 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 5.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303.40 Mn |
| Dec 31, 2025 | 252.52 Mn |
| Sep 30, 2025 | 214.60 Mn |
| Jun 30, 2025 | 223.23 Mn |
| Mar 31, 2025 | 182.24 Mn |
| Dec 31, 2024 | 141.18 Mn |
| Sep 30, 2024 | 149.19 Mn |
| Jun 30, 2024 | 133.25 Mn |
| Mar 31, 2024 | 121.01 Mn |
| Dec 31, 2023 | 137.45 Mn |
| Sep 30, 2023 | 147.98 Mn |